SUPREFACT 1 MG
BUSERELIN (BUSERELIN ACETATE) : 1 MG · DIN 02225166 · CHEPLAPHARM ARZNEIMITTEL GMBH
Health Canada status: MARKETED
What is SUPREFACT?
SUPREFACT 1 MG contains BUSERELIN (BUSERELIN ACETATE) : 1 MG. It is listed in the Health Canada Drug Product Database under DIN 02225166, held by CHEPLAPHARM ARZNEIMITTEL GMBH, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 05-Jun-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SUPREFACT used for?
SUPREFACT (buserelin acetate) is indicated for: Subcutaneous injection: The palliative treatment (initial and maintenance treatment) of patients with hormone-dependent advanced carcinoma of the prostate gland (Stage D). Nasal solution: The palliative treatment (maintenance treatment) of patients with hormone-dependent advanced carcinoma of the prostate gland (Stage D). The treatment of endometriosis in patients who do not require surgery as primary therapy. The duration of treatment is usually six months and should not exceed nine months.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is SUPREFACT called?
The same molecule, BUSERELIN, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Receptal | Latin | Iceland |
| SUPREFACT OLDATOS INJEKCIÓ | Latin | Hungary |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02225166 |
|---|---|
| Brand name | SUPREFACT |
| Generic / active ingredient | BUSERELIN (BUSERELIN ACETATE) : 1 MG |
| Manufacturer | CHEPLAPHARM ARZNEIMITTEL GMBH |
| Strength | 1 MG |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Prescription |
| ATC code | L02AE01 BUSERELIN |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 05-Jun-2020 |
| Original market date | 1996-12-30 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02225166 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2225166 |
| Brand name | SUPREFACT |
| Active ingredient / INN | BUSERELIN (BUSERELIN ACETATE) : 1 MG |
| ATC code | L02AE01 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L02 |
| AHFS class | 10:00.00 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | CHEPLAPHARM ARZNEIMITTEL GMBH |
How is it stored and handled?
null
How is it supplied?
null
Which pack is which?
| Strength on the label | 1 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | SUBCUTANEOUS |
| Packaging as described in the monograph | null |
| Storage | null |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code L02AE01 BUSERELIN. 1 of 7 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| SUPREFACT | 100 MCG | SOLUTION | CHEPLAPHARM ARZNEIMITTEL GMBH | CANCELLED POST MARKET | DIN 02225158 |
| SUPREFACT DEPOT 2 MONTHS | 6.3 MG | IMPLANT | CHEPLAPHARM ARZNEIMITTEL GMBH | DORMANT | DIN 02228955 |
| SUPREFACT DEPOT 3 MONTHS | 9.45 MG | IMPLANT | CHEPLAPHARM ARZNEIMITTEL GMBH | DORMANT | DIN 02240749 |
| SUPREFACT INJ 1MG/ML | 1 MG | LIQUID | HOECHST CANADA INC. | CANCELLED POST MARKET | DIN 00680028 |
| SUPREFACT INTRANASAL SOLUTION 1MG/ML | 1 MG | SPRAY | HOECHST CANADA INC. | CANCELLED POST MARKET | DIN 00680036 |
| SUPREFACT LIQ 1MG/ML | 1 MG | LIQUID | HOECHST ROUSSEL CANADA INC. | CANCELLED POST MARKET | DIN 01989669 |
Who else supplies BUSERELIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BUSERELIN appears in 10 registered pack listings across 6 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does BUSERELIN cost around the world?
BUSERELIN is listed on 5 national price registers Nexara tracks, across 8 pack listings published on 4 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Italy | prezzo al pubblico (classe A) | 4 | 4 | 02 Sep 2026 |
| Greece | producer price (ex-factory) | 1 | 1 | 03 Sep 2026 |
| Hungary | producer price (ex-factory) | 1 | 1 | 03 Sep 2026 |
| Iceland | max wholesale | 1 | 1 | 02 Sep 2026 |
| South Africa | single exit price | 1 | 1 | 01 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.